目的 評(píng)價(jià)脈絡(luò)寧注射液在臨床使用的安全性，挖掘可能造成脈絡(luò)寧注射液不良反應(yīng)的相關(guān)因素，為今后臨床安全使用提供警示和參考。方法 在中國(guó)知網(wǎng)、萬方數(shù)據(jù)庫、維普數(shù)據(jù)庫中以“脈絡(luò)寧注射液”“注射用脈絡(luò)寧”“797注射液”“脈絡(luò)寧”“不良反應(yīng)”“不良事件”“用藥錯(cuò)誤”“高警示藥品”“過敏性休克”為關(guān)鍵詞檢索脈絡(luò)寧注射液所致不良反應(yīng)的文獻(xiàn)，并進(jìn)行整理和分析。結(jié)果 共篩選出文獻(xiàn)131篇，189個(gè)案例。結(jié)果表明，脈絡(luò)寧注射液致不良反應(yīng)多發(fā)生于45～74歲患者，以免疫系統(tǒng)和呼吸系統(tǒng)占多數(shù)（75.6%），脈絡(luò)寧注射液不良反應(yīng)以速發(fā)型為主，主要出現(xiàn)在用藥15min以內(nèi)，發(fā)生不良反應(yīng)的嚴(yán)重程度與脈絡(luò)寧的使用劑量無顯著相關(guān)性。結(jié)論： 脈絡(luò)寧注射液在臨床使用時(shí)應(yīng)嚴(yán)格把握適應(yīng)證及使用方法，用藥前仔細(xì)詢問患者過敏史，加強(qiáng)用藥監(jiān)測(cè)。

Objective To evaluate the safety of Mailuoning Injection in clinical use, and explore the related factors that may cause adverse reactions of Mailuoning Injection, so as to provide warning and reference for future clinical safe use. Method Literature on adverse reactions caused by Mailuoning Injection was retrieved from CNKI, Wanfang, and VIP database with the key words "Mailuoning Injection"" Mailuoning for injection""797 Injection""Mailuoning""adverse reactions""adverse events""medication errors""high-warning drugs""anaphylactic shock" as keywords, and then sorted and analyzed. Result A total of 131 literatures and 189 cases were selected. The results showed that the adverse reactions caused by Mailuoning Injection mostly occurred in patients aged 45-74 years, and the immune system and respiratory system accounted for the majority (75.6%). Adverse reactions of Mailuoning Injection were mainly rapid onset, which mainly occurred within 15 min of administration. The severity of adverse reactions had no significant correlation with the dosage of Mailuoning Injection. Conclusion In the clinical use of Mailuoning Injection, the indications and the method of use should be strictly grasped, the patient's allergy history should be carefully asked before medication, and the medication monitoring should be strengthened.

R914

中國(guó)醫(yī)藥教育協(xié)會(huì)孫思邈中醫(yī)藥科研專項(xiàng)課題（藥教協(xié)授字【2016】第164-8號(hào)）